ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 159 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2018. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,914,354 | +141.5% | 250,052 | +212.4% | 3.00% | +167.2% |
Q2 2023 | $3,691,198 | -65.1% | 80,052 | -69.7% | 1.12% | -61.9% |
Q1 2023 | $10,580,564 | +31.3% | 264,052 | +51.7% | 2.95% | +18.6% |
Q4 2022 | $8,060,348 | +12.0% | 174,052 | 0.0% | 2.49% | +7.8% |
Q3 2022 | $7,197,000 | -95.5% | 174,052 | +1711.2% | 2.31% | +37.4% |
Q2 2022 | $161,100,000 | +7671.3% | 9,610 | -95.9% | 1.68% | +259.0% |
Q1 2022 | $2,073,000 | -82.1% | 233,100 | +68.8% | 0.47% | -81.9% |
Q4 2021 | $11,613,000 | +25.1% | 138,100 | +33.9% | 2.59% | +15.5% |
Q3 2021 | $9,286,000 | +62.0% | 103,100 | +71.5% | 2.24% | +48.1% |
Q2 2021 | $5,731,000 | +150.8% | 60,100 | +199.0% | 1.51% | +150.5% |
Q1 2021 | $2,285,000 | +9.3% | 20,100 | -51.0% | 0.60% | -25.9% |
Q1 2018 | $2,090,000 | – | 41,000 | – | 0.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |